GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms E Walmsley |
|||
b) |
Position/status |
Chief Executive Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
956 |
|
||
|
£17.4100 |
768
|
|
||
|
£17.4100 |
639 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
2,363 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr I Mackay |
|||
b) |
Position/status |
Chief Financial Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
661 |
|
||
|
£17.4100 |
518 |
|
||
|
£17.4100 |
443 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
1,622 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr H Barron |
|||
b) |
Position/status |
Chief Scientific Officer and President, R&D |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$46.2300 |
523 |
|
||
|
$46.2300 |
437 |
|
||
|
$ 46.2300 |
331 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
1,291 $46.2300 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr R Connor
|
|||
b) |
Position/status |
President, Vaccines and Global Health |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
162 |
|
||
|
£17.4100 |
242 |
|
||
|
£17.4100 |
140 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
544 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Conrad |
|||
b) |
Position/status |
Chief People Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
150 |
|
||
|
£17.4100 |
99 |
|
||
|
£17.4100 |
92 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
341 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr J Ford |
|||
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
184 |
|
||
|
£17.4100 |
142 |
|
||
|
£17.4100 |
111 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
437 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms S Jackson |
|||
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
86 |
|
||
|
£17.4100 |
60 |
|
||
|
£17.4100 |
56 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
202 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr B McNamara |
|||
b) |
Position/status |
CEO, GSK Consumer Healthcare |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$46.2300 |
55 |
|
||
|
$46.2300 |
80 |
|
||
|
$46.2300 |
101 |
|
||
|
|
|
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
236 $46.2300 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr L Miels |
|||
b) |
Position/status |
Chief Commercial Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
314 |
|
||
|
£17.4100 |
232 |
|
||
|
£17.4100 |
173 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
719 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms S Ramakrishnan |
|||
b) |
Position/status |
Chief Digital and Technology Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$46.2300 |
31 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr D Redfern |
|||
b) |
Position/status |
Chief Strategy Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
208 |
|
||
|
£17.4100 |
170 |
|
||
|
£17.4100 |
136 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
514 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr R Simard |
|||
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
189 |
|
||
|
£17.4100 |
120 |
|
||
|
£17.4100 |
102 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
411 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr P Thomson |
|||
b) |
Position/status |
President, Global Affairs |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£17.4100 |
131 |
|
||
|
£17.4100 |
98 |
|
||
|
£17.4100 |
79 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
308 £17.4100 |
||||
e) |
Date of the transaction |
2022-04-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.4100 | 138 |
| ||
| £17.4100 | 163 |
| ||
|
|
|
| ||
d) | Aggregated information
|
| |||
Aggregated volume Price |
301 £17.4100 | ||||
e) | Date of the transaction | 2022-04-08 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |